Canadian researchers found that a personalized therapeutic intervention fingerprint created from multiple PET and MRI modes, computational brain modeling and artificial intelligence was able to predict the efficacy of drugs that target amyloid and tau accumulation, inflammation and neuronal dysfunction, which are linked to Alzheimer's disease and dementia. The findings in the journal NeuroImage may prompt personalized treatments based on patients' brain characteristics and gene expression profiles, as well as reduce clinical trial costs, researchers said.
PET, MRI-based therapeutic fingerprint may help predict drug efficacy
Sign up for SNMMI SmartBrief
Nuclear medicine and molecular imaging news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.